Halozyme Therapeutics SG&A Expenses 2010-2024 | HALO

Halozyme Therapeutics sg&a expenses for the twelve months ending June 30, 2024 were $0.144B, a 3.23% decline year-over-year.

  • Halozyme Therapeutics annual sg&a expenses for 2023 were $0.149B, a 3.94% increase from 2022.
  • Halozyme Therapeutics annual sg&a expenses for 2022 were $0.144B, a 185.21% increase from 2021.
  • Halozyme Therapeutics annual sg&a expenses for 2021 were $0.05B, a 10.03% increase from 2020.

Halozyme Therapeutics SG&A Expenses 2010-2024 | HALO

  • Halozyme Therapeutics annual sg&a expenses for 2023 were $0.149B, a 3.94% increase from 2022.
  • Halozyme Therapeutics annual sg&a expenses for 2022 were $0.144B, a 185.21% increase from 2021.
  • Halozyme Therapeutics annual sg&a expenses for 2021 were $0.05B, a 10.03% increase from 2020.